Our faculty author, co-author and contribute to more than 1500 peer-reviewed scientific publications each year. Find their recent publications below, and filter by division.
Search the faculty directory to find an individual's list of publications.
Publications
Uronis, H. E., K. Bullock, G. Blobe, S. Hsu, M. Morse, A. Nixon, S. Haley, M. O’Neill, H. Hurwitz, and J. Bendell. “A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e15506.
PMID
27962236
Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 4080.
PMID
27961646
Sathornsumetee, S., A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
Starodub, A., J. Jia, S. Cushman, D. Marshall, H. I. Hurwitz, and A. B. Nixon. “Dual inhibition of αV integrins and Src kinase activity in colon cancer cells.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e14609.
PMID
27964163
Abernethy, A. P., S. Y. Zafar, R. Coeytaux, K. Rowe, J. L. Wheeler, and H. K. Lyerly. “Electronic patient-reported data capture as the foundation of a learning health care system.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
Stinchcombe, T. E., L. Hodgson, J. E. Herndon, M. J. Kelley, M. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, M. R. Green, and E. E. Vokes. “Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on T-Reg counts and EGFRvIII-specific immune responses in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 3551.
PMID
27961368
Abernethy, A. P., S. Y. Zafar, R. Coeytaux, K. Rowe, J. L. Wheeler, and H. K. Lyerly. “Electronic patient-reported data capture as the foundation of a learning health care system.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 6522.
PMID
27964028
Kondo, S., E. M. Sturgis, F. Li, Q. Wei, and G. Li. “GSTM1 and GSTT1 null polymorphisms and risk of salivary gland carcinoma.” International Journal of Clinical and Experimental Medicine 2, no. 1 (May 19, 2009): 68–75.